title: Effect of serotonin on vasopressin release: a comparison to corticosterone, prolactin and renin.
abstract: Previously we reported that 5 min after intracerebroventricular (i.c.v.) injection, serotonin (5-HT, 2.5 micrograms) produced increases in blood pressure and decreases in heart rate in conscious rats that were blocked by LY 53857 (a selective 5-HT2/1C antagonist) and were sensitive to vasopressin antagonism. The present studies were performed to determine if this dose of 5-HT acts similarly to increase plasma vasopressin levels. In addition, the vasopressin responses were compared to prolactin, corticosterone, and plasma renin activity, three other neuroendocrine systems regulated in part by 5-HT. The administration of 5-HT (2.5 micrograms i.c.v.) produced a rapid (maximum response in less than 5 min) and brief (return to baseline by 15 min) increase in plasma vasopressin levels. The response was eliminated by the centrally acting 5-HT2/1C antagonist LY 53857 (100 micrograms/kg i.v.), but only attenuated by xylamidine (100 micrograms/kg i.v.), a 5-HT2/1C antagonist that reportedly does not cross the blood-brain barrier. 5-HT also increased plasma prolactin and corticosterone levels, but neither LY 53857 nor xylamidine altered these responses. In rats rendered chronically baroreceptor deficient by sinoaortic deafferentation, the vasopressin response to 5-HT was reduced, whereas the prolactin response was normal. 5-HT did not increase plasma renin activity in intact or baroreceptor-deficient rats, in contrast to the other neuroendocrine systems studied. Thus, the data demonstrate that vasopressin levels are elevated briefly following 5-HT i.c.v., consistent with the pharmacologic profile of the early cardiovascular response.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City 66160-7417.
authors.forename: P E
authors.initials: PE
authors.lastname: Pérgola
authors.forename: A F
authors.initials: AF
authors.lastname: Sved
authors.forename: J L
authors.initials: JL
authors.lastname: Voogt
authors.forename: R H
authors.initials: RH
authors.lastname: Alper
mesh_terms: D000578:Amidines / Q000494:pharmacology; D000818:Animals; D003345:Corticosterone / Q000097:blood* / Q000378:metabolism; D003714:Denervation; D004873:Ergolines / Q000494:pharmacology; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D011311:Pressoreceptors / Q000502:physiology; D011388:Prolactin / Q000097:blood* / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012083:Renin / Q000097:blood*; D012701:Serotonin / Q000008:administration & dosage / Q000494:pharmacology*; D012702:Serotonin Antagonists / Q000494:pharmacology; D012850:Sinus of Valsalva / Q000294:innervation / Q000502:physiology; D014667:Vasopressins / Q000097:blood* / Q000378:metabolism
chemical_list: D000578:Amidines; D004873:Ergolines; D012702:Serotonin Antagonists; D014667:Vasopressins; D012701:Serotonin; D011388:Prolactin; D012083:Renin; C032663:LY 53857; C005894:xylamidine; D003345:Corticosterone